-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Oncternal Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Oncternal Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$8.68M, a 16.4% increase year-over-year.
- Oncternal Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$36M, a 18.3% increase year-over-year.
- Oncternal Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$41.7M, a 7.19% increase from 2022.
- Oncternal Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$44.9M, a 43.3% decline from 2021.
- Oncternal Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$31.4M, a 78.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)